Thus, suggesting that the pro-tumorigenic activity of RNF4 is multifaceted and that the RNF4-RGMb-BMP6 pathway acts primarily as a pro-survival pathway in sarcomas and therapy-resistant cells, and that BMP6 and RGMb inhibition has a potent anti-cancer activity. This evidence concerns the gene RNF4 and sarcoma.